Sign in to view content

Treatment Effect of Intravitreal Aflibercept Injection by Baseline Factors in Moderately Severe-to-Severe NPDR in PANORAMA

Nathan C. Steinle, MD

Video
Published 2020

Related

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema
Victor Hugo Gonzalez, MD
Updates from the Field
2024
Intraoperative Fluorescein Angiography to Efficiently Identify Many Biomarkers and Guide Surgical Decision-Making
Alan J. Franklin, MD, PhD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more